三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种雌激素受体、孕激素受体和人类表皮生长因子受体2阴性的乳腺癌亚型,其侵袭性及疾病进展速度明显高于其他亚型.目前其主要治疗为手术联合化疗,但晚期TNBC患者的治疗效果不佳.随着对TNBC免疫微环境深入研究,免疫疗法已显示出潜在的治疗价值.TNBC免疫治疗主要包括免疫检查点阻断剂、细胞治疗、肿瘤疫苗以及调整肿瘤微环境.该文对免疫疗法的现状和进展作回顾及总结,有助于TNBC免疫治疗的新认识.
Advances in clinical application of immunotherapy for triple-negative breast cancer
Triple-negative breast cancer(TNBC)is a subtype of breast cancer that is negative for estrogen receptors,progesterone receptors,and human epidermal growth factor receptor 2,and is significantly more aggressive and progressive than other subtypes.At present,the main treatment is surgery combined chemotherapy,but treatment efficacy of the advanced TNBC patients is poor.With the in-depth study of TNBC immune microenvironment,immunotherapy has shown potential therapeutic value.The immunotherapy of TNBC mainly includes immune checkpoint blockers,cell therapy,tumor vaccines and adjustment of tumor microenvironment.This article reviewed and summarized the current status and progress of immunotherapy,which contributed to the new understanding of TNBC immunotherapy.
triple-negative breast cancerimmunotherapytumor microenvironment
NETL
NSTL
万方数据
